# PDUFA dates May 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-05

> 48 FDA catalysts are dated in May 2027, including 7 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in May 2027?

PDUFA dates in May 2027: reboxetine (AXSM) on May 1, 2027; ifezuntirgene inilparvovec (QURE) on May 1, 2027; encaleret (BBIO) on May 8, 2027; mezigdomide (BMY) on May 13, 2027; obexelimab (ZBIO) on May 27, 2027; KHINDIVI® (hydrocortisone, ETON) on May 28, 2027; and 1 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2027-05)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-442628, https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-02. Cite: https://sec-api.dev/fda-calendar/2027-05#answer

## PDUFA dates in May 2027

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| May 1, 2027 | Axsome Therapeutics, Inc. | AXSM | reboxetine | cataplexy in narcolepsy | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm) |
| May 1, 2027 | uniQure N.V. | QURE | ifezuntirgene inilparvovec |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm) |
| May 8, 2027 | BridgeBio Pharma, Inc. | BBIO | encaleret |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm) |
| May 13, 2027 | BRISTOL MYERS SQUIBB CO | BMY | mezigdomide | relapsed or refractory multiple myeloma | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm) |
| May 27, 2027 | Zenas BioPharma, Inc. | ZBIO | obexelimab |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm) |
| May 28, 2027 | Eton Pharmaceuticals, Inc. | ETON | KHINDIVI® (hydrocortisone) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm) |
| May 30, 2027 | BIOMARIN PHARMACEUTICAL INC | BMRN | VOXZOGO (vosoritide) | Hypochondroplasia | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm) |

## All catalysts in May 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 1, 2027 | [Reboxetine PDUFA date](https://sec-api.dev/pdufa/reboxetine) | AXSM | cataplexy in narcolepsy | scheduled | "AXS-12 for cataplexy in narcolepsy, PDUFA target action (May 1, 2027)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm)) |
| May 1, 2027 | [Ifezuntirgene inilparvovec PDUFA date](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | scheduled | "~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm)) |
| May 2027 | [Cibinqo (abrocitinib) primary completion](https://sec-api.dev/pdufa/abrocitinib) | PFE | Eczema | scheduled | "NCT06807268 (A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807268)) |
| May 2027 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Breast Cancer; HER2-positive; Metastatic | scheduled | "NCT04784715 (Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04784715)) |
| May 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Cancer; Anal Carcinoma; Anal Cancer | scheduled | "NCT02628067 (Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02628067)) |
| May 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Gastric Cancer | scheduled | "NCT04379596 (Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04379596)) |
| May 2027 | [Romosozumab primary completion](https://sec-api.dev/pdufa/romosozumab) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT05972551 (Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05972551)) |
| May 2027 | [GSK3862995B primary completion](https://sec-api.dev/pdufa/gsk3862995b) | GSK | Bronchiectasis | scheduled | "NCT07201051 (A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07201051)) |
| May 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | scheduled | "NCT04380636 (Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04380636)) |
| May 2027 | [WELIREG® (belzutifan) primary completion](https://sec-api.dev/pdufa/belzutifan) | MRK | Metastatic Breast Cancer | scheduled | "NCT06428396 (Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06428396)) |
| May 2027 | [Aubagio (teriflunomide) primary completion](https://sec-api.dev/pdufa/teriflunomide) | SNY | Multiple Sclerosis | scheduled | "NCT06141473 (Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141473)) |
| May 8, 2027 | [INTEGRATED BIOPHARMA INC interim data readout](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | scheduled | "After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements at least through the period ending May 8, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1016504/000143774926015899/inbp20260331_10q.htm)) |
| May 8, 2027 | [Encaleret PDUFA date](https://sec-api.dev/pdufa/encaleret) | BBIO |  | scheduled | "Encaleret for ADH1 PDUFA date set for May 8, 2027, with Priority Review; MAA submitted to EMA U.S. launch upon FDA approval" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| May 2027 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Atherosclerotic Cardiovascular Disease | scheduled | "NCT05030428 (Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05030428)) |
| May 2027 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06074588 (Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074588)) |
| May 2027 | [Cagrilintide primary completion](https://sec-api.dev/pdufa/cagrilintide) | NVO | Obesity; Overweight | scheduled | "NCT07220642 (Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-11 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220642)) |
| May 2027 | [Cagrilintide primary completion](https://sec-api.dev/pdufa/cagrilintide) | NVO | Overweight; Obesity; Type 2 Diabetes | scheduled | "NCT07220759 (Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-12 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220759)) |
| May 13, 2027 | [Mezigdomide PDUFA date](https://sec-api.dev/pdufa/mezigdomide) | BMY | relapsed or refractory multiple myeloma | scheduled | "The FDA accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm)) |
| May 2027 | [ARAKODA® (tafenoquine) primary completion](https://sec-api.dev/pdufa/tafenoquine) | GSK | Malaria, Vivax | scheduled | "NCT06666491 (An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06666491)) |
| May 2027 | [CDR132L primary completion](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979375 (A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979375)) |
| May 2027 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Adult; Healthy Participants | scheduled | "NCT07819097 (A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07819097)) |
| May 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06736041 (Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06736041)) |
| May 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06799000 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06799000)) |
| May 2027 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Symptomatic Venous Thromboembolism (VTE) | scheduled | "NCT07213778 (REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213778)) |
| May 2027 | [GIA632 primary completion](https://sec-api.dev/pdufa/gia632) | NVS | Atopic Dermatitis | scheduled | "NCT07220577 (Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220577)) |
| May 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671483 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671483)) |
| May 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671496 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671496)) |
| May 2027 | [Cagrilintide primary completion](https://sec-api.dev/pdufa/cagrilintide) | NVO | Overweight; Obesity | scheduled | "NCT07745504 (A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07745504)) |
| May 2027 | [Nemtabrutinib primary completion](https://sec-api.dev/pdufa/nemtabrutinib) | MRK | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624554)) |
| May 2027 | [Biib017 (peginterferon beta-1a) primary completion](https://sec-api.dev/pdufa/biib017-peginterferon-beta-1a) | BIIB | Multiple Sclerosis, Relapsing-Remitting | scheduled | "NCT03958877 (A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-20 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03958877)) |
| May 2027 | [Cd19 t-hank- iv administration primary completion](https://sec-api.dev/pdufa/cd19-t-hank-iv-administration) | IBRX | Relapsed B-Cell Non Hodgkin Lymphoma | scheduled | "NCT07125872 (Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-25 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07125872)) |
| May 2027 | [BMS-986368 primary completion](https://sec-api.dev/pdufa/bms-986368) | BMY | Multiple Sclerosis Spasticity | scheduled | "NCT06782490 (A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-26 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06782490)) |
| May 27, 2027 | [Obexelimab PDUFA date](https://sec-api.dev/pdufa/obexelimab) | ZBIO |  | scheduled | "PDUFA target action date of May 27, 2027, following FDA acceptance of Obexelimab BLA submission for the treatment of IgG4-RD in second quarter 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm)) |
| May 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Endometrial Neoplasms | scheduled | "NCT05173987 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05173987)) |
| May 28, 2027 | [KHINDIVI® (hydrocortisone) PDUFA date](https://sec-api.dev/pdufa/hydrocortisone) | ETON |  | scheduled | "KHINDIVI label expansion Prior Approval Supplement (PAS) accepted for review and assigned May 28, 2027 PDUFA date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm)) |
| May 2027 | [Voydeya (danicopan) primary completion](https://sec-api.dev/pdufa/danicopan) | AZN | Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis | scheduled | "NCT06449001 (Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449001)) |
| May 2027 | [ALN-4324 primary completion](https://sec-api.dev/pdufa/aln-4324) | ALNY | Type 2 Diabetes Mellitus (T2DM) | scheduled | "NCT07465224 (A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07465224)) |
| May 2027 | [Laroprovstat/rosuvastatin 1 primary completion](https://sec-api.dev/pdufa/laroprovstat-rosuvastatin-1) | AZN | Hypercholesterolaemia | scheduled | "NCT07619118 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619118)) |
| May 30, 2027 | [VOXZOGO (vosoritide) PDUFA date](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | scheduled | "PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm)) |
| May 2027 | [Prexasertib primary completion](https://sec-api.dev/pdufa/prexasertib) | ACRV | Endometrial Adenocarcinoma | scheduled | "NCT05548296 (A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-30 (ESTIMATED); Lead Sponsor Acrivon Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05548296)) |
| May 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Palmoplantar Psoriasis | scheduled | "NCT07752108 (A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-05-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07752108)) |
| May 2027 | [Study drug active primary completion](https://sec-api.dev/pdufa/study-drug-active) | CGTX | Early Alzheimer's Disease | scheduled | "NCT05531656 (A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Cognition Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05531656)) |
| May 2027 | [ELEVIDYS (delandistrogene moxeparvovec) primary completion](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) | SRPT | Duchenne Muscular Dystrophy | scheduled | "NCT05881408 (A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Sarepta Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05881408)) |
| May 2027 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06120140 (Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06120140)) |
| May 2027 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Chronic Hepatitis B Virus Infection; Hepatitis B | scheduled | "NCT06537414 (A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06537414)) |
| May 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06628908 (Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628908)) |
| May 2027 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT06935357 (A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06935357)) |
| May 2027 | [Tanruprubart primary completion](https://sec-api.dev/pdufa/tanruprubart) | ANNX | Guillain-Barre Syndrome | scheduled | "NCT07020819 (An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Annexon, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07020819)) |

Other months: https://sec-api.dev/fda-calendar/2027-04 , https://sec-api.dev/fda-calendar/2027-06. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates May 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-05

```bibtex
@misc{secapidev_fda_calendar_2027_05_20261116,
  title        = {PDUFA dates May 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-05}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_05_20261116","title":"PDUFA dates May 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-05","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
